China (Mainland)
Premiumsupplier
Isoniazid Manufacturer 54-85-3 For Antibacterial With Factory Price CAS NO.54-85-3
- Min.Order: 10 Gram
- Payment Terms: T/T,MoneyGram
- Product Details
Keywords
- 99% Isoniazid
- Isoniazid Manufacturer
- Antibacterial
Quick Details
- ProName: Isoniazid Manufacturer 54-85-3 For Ant...
- CasNo: 54-85-3
- Molecular Formula: C6H7N3O
- Appearance: White Powder
- Application: It Can Be Used As Pharmaceutical Inte...
- DeliveryTime: 2-4 days after confirming your payment...
- PackAge: 100g/ bag, 2 kg/ bag, 25kg/ carton or ...
- Port: Wuhan
- ProductionCapacity: 10000 Metric Ton/Month
- Purity: 99%
- Storage: Store in sealed containers at cool & d...
- Transportation: By DHL, TNT, FedEx, HKEMS, UPS, Etc
- LimitNum: 10 Gram
Superiority
Advantages:
Hubei XinRunde Chemical Co., Ltd is a renowned pharmaceutical manufacturer. We can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. Never stop striving to offer our best service is our philosophy. We have Flexible and Untraceable payment terms. As a leading manufacture, our products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Brazil, Mexico, Australia, Japan, Korea, Thailand, Indonesia, Uruguay and many other countries.
1. Quality.Every batch of steroid powders have tobetested by our QC(quality control) before they are allowed to sell.
2. Delivery We have stock, so we can delivery quickly at the very day when receive the payment. Within 24 hours after receiving the payment Lead time 4 or 7 days.
3. Discreet package Safelyand Professionally Disguised Package Guaranteed. For your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate.
4. Warm after-sale service Any of your question would be solved for the first as soon as possible.
Details
| Isoniazid Basic information |
| Product Name: | Isoniazid |
| Synonyms: | 4-PYRIDINECARBOHYDRAZIDE;4-PYRIDINECARBOXYLIC ACID HYDRAZIDE;AKOS BBS-00004103;HYCOZID;LABOTEST-BB LT00146690;INAH;ISONICOTINIC ACID HYDRAZIDE;ISONIAZIDE |
| CAS: | 54-85-3 |
| MF: | C6H7N3O |
| MW: | 137.14 |
| EINECS: | 200-214-6 |
| Product Categories: | NYDRAZID;Antituberculotic;AMIDE;Amines;Aromatics;API;-;Intermediates & Fine Chemicals;Pharmaceuticals |
| Mol File: | 54-85-3.mol |
|
|
|
| Isoniazid Chemical Properties |
| Melting point | 171-173 °C(lit.) |
| Boiling point | 251.97°C (rough estimate) |
| density | 1.2620 (rough estimate) |
| refractive index | 1.6910 (estimate) |
| Fp | >250°C |
| storage temp. | Refrigerator |
| solubility | 125g/l |
| form | Crystals or Crystalline Powder |
| pka | pKa 2.00/3.60/10.8(H2O) (Uncertain) |
| color | White or colorless |
| PH | 6-8 (50g/l, H2O, 20℃) |
| Water Solubility | 14 g/100 mL (25 ºC) |
| Sensitive | Air Sensitive |
| Merck | 14,5186 |
| BRN | 119374 |
| Stability: | Stability Stable, but may be air or light sensitive. Combustible. Incompatible with strong oxidizing agents, chloral, aldehydes, iodine, ferric salts, hypochlorites. |
| InChIKey | QRXWMOHMRWLFEY-UHFFFAOYSA-N |
| CAS DataBase Reference | 54-85-3(CAS DataBase Reference) |
| NIST Chemistry Reference | Isoniazid(54-85-3) |
| EPA Substance Registry System | 4-Pyridinecarboxylic acid, hydrazide(54-85-3) |
| Safety Information |
| Hazard Codes | Xn |
| Risk Statements | 22-38-40-36/37/38 |
| Safety Statements | 37-36/37/39-26 |
| RIDADR | 2811 |
| WGK Germany | 3 |
| RTECS | NS1751850 |
| TSCA | Yes |
| PackingGroup | III |
| HS Code | 29333999 |
| Hazardous Substances Data | 54-85-3(Hazardous Substances Data) |
| Toxicity | LD50 in mice (mg/kg): 151 i.p., 149 i.v. (Jenney, Pfeiffer) |
| Isoniazid Usage And Synthesis |
| Chemical Properties | white crystalline powder |
| Uses | antibacterial, tuberculostatic |
| Uses | Antibiotic for treatment of Mycobacterium tuberculosis, inhibits mycolic acid biosynthesis. Metabolized by hepatic N-acetyltransferase (NAT) and cytochrome P450 2E1 (CYP2E1) to form hepatotoxins. Sele ctively induces expression of CYP2E1. Reversibly inhibits CYP2C19 and CYP3A4 activities, and mechanistically inactivates CYP1A2, CYP2A6, CYP2C19 and CYP3A4 at clinically relevant concentrations. Antib acterial (tuberculostatic). |
| Uses | For the treatment of all forms of tuberculosis in which organisms are susceptible. |
| Definition | ChEBI: A carbohydrazide obtained by formal condensation between pyridine-4-carboxylic acid and hydrazine. |
| Brand name | Inh (Novartis); Nydrazid (Bristol-Myers Squibb); Nydrazid (Sandoz); Rimifon (Roche). |
| Antimicrobial activity | Susceptibility to isoniazid is virtually restricted to the M. tuberculosis complex (MIC 0.01–0.2 mg/L). It is highly bactericidal against actively replicating M. tuberculosis. Other mycobacteria are resistant, except for some strains of M. xenopi (MIC 0.2 mg/L) and a few strains of M. kansasii (MIC 1 mg/L). |
| Acquired resistance |
Mutations in the katG gene, the inhA gene or its promoter region, and in the intergenic region of the oxyR–ahpC locus confer resistance to isoniazid. The relative proportions of such mutations vary geographically and are related to the distribution of the various lineages or superfamilies of M. tuberculosis. Isoniazid resistance is the commonest form of drug resistance worldwide and the great majority of strains resistant to another agent are also resistant to isoniazid. |
| General Description | Odorless colorless or white crystals or white crystalline powder. Taste is slightly sweet at first and then bitter. pH (1% aqueous solution) 5.5-6.5. pH (5% aqueous solution) 6-8. |
| Air & Water Reactions | Sensitive to air and light. Absorbs insignificant amounts of moisture at 77°F at relative humidities up to approximately 90%. Water soluble. Dust can be explosive when suspended in air at specific concentrations. |
| Reactivity Profile | Isoniazid is incompatible with chloral, aldehydes, iodine, hypochlorites and ferric salts. Isoniazid is also incompatible with oxidizers. Isoniazid may react with sugars and ketones. Isoniazid can react as a weak acid or a weak base. Isoniazid can be decomposed by oxidative and reductive reactions. |
| Fire Hazard | Isoniazid is combustible. |
| Pharmaceutical Applications | One of a number of nicotinamide analogs found to have antituberculosis activity, following the observation that nicotinamide inhibited the replication of M. tuberculosis. It is soluble in water. The dry powder is stable if protected from light. It is a prodrug requiring oxidative activation by KatG, a mycobacterial catalase–peroxidase enzyme. |
| Pharmacokinetics |
Oral absorption: >95% Cmax 300 mg oral: 3–5 mg/L after 1–2 h Plasma half-life: 0.5–1.5 h (rapid acetylators) : 2–4 h (slow acetylators) Volume of distribution: 0.6–0.8 L/kg Plasma protein binding: Very low Absorption and distribution Isoniazid is almost completely absorbed from the gut and is well distributed. Absorption is impaired by aluminum hydroxide. Therapeutic concentrations are achieved in sputum and CSF. It crosses the placenta and is found in breast milk. Metabolism Isoniazid is extensively metabolized to a variety of pharmacologically inactive derivatives, predominantly by acetylation. As a result of genetic polymorphism, patients are divisible into rapid and slow acetylators. About 50% of Caucasians and Blacks, but 80–90% of Chinese and Japanese, are rapid acetylators. Acetylation status does not affect the efficacy of daily administered therapy. The rate of acetylation is reduced in chronic renal failure. Excretion Nearly all the dose is excreted in the urine within 24 h, as unchanged drug and metabolic products. |
| Clinical Use |
Isonicotinic acid hydrazide, isonicotinyl hydrazide, or INH(Nydrazid) occurs as a nearly colorless crystalline solid thatis very soluble in water. It is prepared by reacting the methylester of isonicotinic acid with hydrazine. Isoniazid is a remarkably effective agent and continuesto be one of the primary drugs (along with rifampin, pyrazinamide,and ethambutol) for the treatment of tuberculosis.It is not, however, uniformly effective against all formsof the disease. The frequent emergence of strains of the tuberclebacillus resistant to isoniazid during therapy wasseen as the major shortcoming of the drug. This problemhas been largely, but not entirely, overcome with the use ofcombinations. The activity of isoniazid is manifested on the growing tuberclebacilli and not on resting forms. Its action, which isconsidered bactericidal, is to cause the bacilli to lose lipidcontent by a mechanism that has not been fully elucidated.The most generally accepted theory suggests that the principaleffect of isoniazid is to inhibit the synthesis of mycolicacids, high–molecular-weight, branched β-hydroxyfatty acids that constitute important components of the cellwalls of mycobacteria. |
| Clinical Use |
Tuberculosis (intensive and continuation phases) Prevention of primary tuberculosis in close contacts and reactivation disease in infected but healthy persons (monotherapy) |